Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

By N. Mitsiades, C. Mitsiades, V. Poulaki, D. Chauhan, P. Richardson, T. Hideshima, N. Munshi, S. Treon, K. Anderson. Blood, 2002

682 citations recorded by the source corpus.

Subfields: Complementary and alternative medicine, Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/cbef4aa05e2ddb915e270ebcc1b80457698e1512

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar
2. J. Adams

In Molecular Biology

1. P. Richardson
2. T. Hideshima
3. J. Adams
4. S. Rajkumar

Citations in the corpus

• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010, background): “Both bortezomib(11) and the immunomodulatory drugs(13) enhance the activity of dexamethasone, and synergy has been demonstrated between bortezomib and lenalidomide.(13) These preclinical findings have translated into clinical efficacy; bortezomib plus dexamethasone(14,15) and lenalidomide plus dexam”
• The evolution of thalidomide and its IMiD derivatives as anticancer agents (2004, background): “Importantly, other mechanistic details have begun to emerge, including effects on apoptotic pathway”